HLB (028300) Q3 2026 earnings summary

Executive summary

• 9M 2026 revenue rose to ₩72.7bn from ₩55.5bn YoY, while operating loss was ₩73.2bn; net loss narrowed to ₩142.1bn from ₩206.1bn.

• LYRFIGTU received U.S. FDA approval in September for second-line FGFR2 fusion or rearrangement cholangiocarcinoma; lirafugratinib commercialization is moving forward.

Financial highlights

• 9M revenue ₩72.67bn vs ₩55.51bn YoY; gross profit ₩31.72bn vs ₩17.05bn.

• 9M operating loss ₩73.22bn vs ₩74.85bn; net loss ₩142.10bn vs ₩206.11bn; basic and diluted EPS were both -₩1,001 vs -₩1,487.

• Q3 revenue was ₩25.98bn vs ₩22.11bn YoY; Q3 net loss was ₩20.81bn vs ₩76.44bn.

• Operating cash outflow was ₩56.70bn; cash and cash equivalents were ₩41.40bn at quarter-end vs ₩40.98bn at FY 2025-end.

Outlook and guidance

• LYRFIGTU is planned for global commercialization and launch following FDA approval; an EMA marketing application was filed in September.

• Rivoceranib plus camrelizumab liver-cancer NDA resubmission followed a third FDA CRL; a further resubmission was filed Oct. 9, after quarter-end.

• ITI-5000 for triple-negative breast cancer and ITI-9001 for Japanese cedar allergy entered Phase 1; additional FGFR2-altered solid-tumor trials are underway.